Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIP-205
- Development stage
- Preclinical
- Lead developer
- AIP
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AIP-205 is a preclinical-stage radiopharmaceutical diagnostic agent being developed by Advanced Innovative Partners (AIP Medical) for the detection and imaging of solid tumors. As a radiopharmaceutical diagnostic, it is designed to target specific biomarkers associated with solid malignancies to facilitate visualization via medical imaging techniques such as PET or SPECT. While the specific molecular target and the radioisotope used in the formulation have not been publicly disclosed, the candidate is part of AIP Medical's specialized pipeline focused on advancing oncology diagnostics and therapeutics through nuclear medicine.
Beyond the preview
Go deeper on AIP-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP-205.